• The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2,3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3±2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non—small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.
(Arch Intern Med 1985;145:449-452)
Ryzen E, Martodam RR, Troxell M, et al. Intravenous Etidronate in the Management of Malignant Hypercalcemia. Arch Intern Med. 1985;145(3):449–452. doi:10.1001/archinte.1985.00360030089018
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: